Post-mortem studies have indicated that GluN1/GluN2B heterodimer expression significantly decreases with increasing AD pathology, whereas GluN1/GluN2A receptors (another form of the fast NMDA receptor) remain unchanged (Mishizen-Eberz et al., 2004). The gene discussed is GRIN2B; the disease is Alzheimer disease.